Encouraged by these data, we intended to evaluate the therapeutic potential of a dual kinase inhibitor targeting both HER2 and EGFR for the treatment of endometrial cancer and proposed to define markers that may help identify patient subsets that would preferentially benefit from such a target-based therapy. The gene discussed is EGFR; the disease is endometrial cancer.